Search Results 1531-1540 of 19490 for Myocardium

1. Veliparib and Topotecan Hydrochloride in Treating Patients with Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer - Mayo Clinic

   History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular ...

2. Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer - Mayo Clinic

   Patient must not have myocardial infarction within 90 days prior to randomization. Patient must not have unstable arrhythmias or unstable angina. Patient ...

3. Nilotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia - Mayo Clinic

   History of myocardial infarction ≤ 12 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular ...

4. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   History or presence within the last 12 months of myocardial infarction, clinically relevant valvular heart disease, or congestive heart failure within the last ...

5. Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis - Mayo Clinic

   Recent myocardial infarction (≤ 30 days); Uncontrolled infection. Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) ...

6. A Study to Investigate the Effectiveness and Safety of Fenfluramine Hydrochloride as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome - Mayo Clinic

   Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke, or ...

7. Phase 3 Study to Treat Patients with Soft Tissue Sarcomas - Mayo Clinic

   Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.

8. Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   2 History of myocardial infarction ≤6 months prior to pre-registration, and/or congestive heart failure requiring ongoing treatment such as medications and ...

9. Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia - Mayo Clinic

   Stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to Screening 13. If female, pregnant or ...

10. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis - Mayo Clinic

    ... myocardial infarction. History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ...